New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Non-Hodgkin Lymphoma: About this Condition
Ìý
About Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma is a cancer. Like other cancers, it starts when cells grow out of control, multiplying and crowding other normal cells.
Non-Hodgkin lymphoma starts in the lymph system, which contains the lymph nodes, spleen, and bone marrow. The lymph system is part of the body’s immune system that protects it from infections and diseases.
Lymph nodes contain the lymph fluid that carries white blood cells through a network of thin tubes spreading through the body.
Stanford ÌÇÐÄ´«Ã½ breakthroughs
Diagnosis & prognosis
Lymphoma Program physicians lead the field in the application of genetic technology to fight cancer. For example, ÌÇÐÄ´«Ã½ers at the Cancer Center have identified a set of six genes that may predict response to treatment in patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkins lymphoma.
This finding is the first gene-based screen to identify people who need the most aggressive therapy. Stanford ÌÇÐÄ´«Ã½ers also recently discovered a simpler yet as accurate 2 gene signature. This test can be done on a small piece of the tumor obtained at diagnosis.
Patients treated by physicians in the Lymphoma Program have access to this kind of predictive genetic screening through ongoing clinical studies in both DLBCL and follicular lymphoma.
WHAT TO EXPECT
The Lymphoma Program specializes in the diagnosis and treatment of all types of Lymphoma, including Non-Hodgkin Lymphoma.
As you and your family prepare for your care at Stanford, you’ll likely have many questions. We are here to help you in any way we can and to partner with you before, during and after treatment.Ìý
Treatments
In 1994, Stanford investigators were the first to treat patients with rituximab, an antibody developed by Dr. Ronald Levy which targets the lymphoma cells. Three years later, rituximab was approved by the FDA and today is the standard therapy for almost all patients with non-Hodgkins lymphoma.
In 2011, Stanford ÌÇÐÄ´«Ã½ers discovered a second antibody which boosts the immune response and dramatically increases the ability of rituximab to kill lymphoma. Patients at Stanford are receiving this novel combination of antibodies through clinical trials.
Stanford investigators have cured many mice with lymphoma in the hope of finding a cure for humans. Based on very promising mouse studies, Stanford investigators recently started a clinical trial testing a "personalized" vaccine for mantle cell lymphoma. Patients at Stanford have access to these and other state-of-the-art therapies.
INTERESTED IN AN ONLINE SECOND OPINION?
The Stanford Medicine Online Second Opinion program offers you easy access to our world-class doctors. It’s all done remotely, and you don’t have to visit our hospital or one of our clinics for this service. You don’t even need to leave home!
Visit our online second opinion page to learn more.
Clinical Trials for Non-Hodgkin's Lymphoma
Clinical trials are ÌÇÐÄ´«Ã½ studies that evaluate a new medical approach, device, drug, or other treatment. As a ÌÇÐÄ´«Ã½ patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Ìý
Our Clinics


Palo Alto, CA 94304
Phone: 650-498-6000 Getting Here
Learn More About Non-hodgkin Lymphoma
What We Offer
Our providers use leading edge techniques to diagnose and treat Non-hodgkin Lymphoma. Learn More
About this Condition
Learn about the symptoms, types, and diagnosis of Non-hodgkin Lymphoma.
Patient Care Resources for Lymphoma
Learn what to expect as you go through the early steps of your care.
To schedule an appointment, please call: 888-888-8888